Investigational New Drugs **9:** 387–390, 1991.

CONTENTS VOL. 9, 1991

Preclinical Studies

Preclinical antitumor activity of CI-973,[SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato(2-)](2 methyl-1,4-butanediamine-N,N′)platinum – A.J. Kraker, C.W. Moore, B.J. Roberts, W.R. Leopold, W.L. Elliott 1

Cyclopentenyl cytosine: Interspecies predictions based on rodent plasma and urine kinetics – D.S. Zaharko, J.A. Kelley, J.E. Tomaszewski, L. Hegedus, N.R. Hartman 9

Multipolar mitotic cells in the human cell line NHIK 3025 following treatment with the mitotic inhibitor NY 4137 – M.E. Holm Juul, J.M. Dornish, P.E. Schwarze, E.O. Pettersen, R. Oftebro 19

Relationship between glutathione levels and drug or radiation sensitivities in human gastric cancer cell lines *in vitro* – S.C. Barranco, B. Weintraub, K.K. MacLean, E.G. Beasley, V.K. Jenkins, C.M. Townsend Jr. 29

Phase I Studies

A phase I trial of recombinant alpha-2a interferon (Roferon-A) with weekly cisplatinum – K. Dhingra, M. Talpaz, H.M. Dhingra, J.A. Ajani, J.M. Rothberg, J.U. Gutterman 37

Crisnatol mesylate: Phase I dose escalation by extending infusion duration – E.A. Poplin, G.G. Chabot, R.L. Tuttle, S. Lucas, W.A. Wargin, L.H. Baker 41

Phase I evaluation of spirogermanium and 5-fluorouracil in colorectal carcinoma – S.K. Williamson, M. Slavik 49

Phase I-II study of pibenzimol hydrochloride (NSC 322921) in advanced pancreatic carcinoma – S.R. Patel, L.K. Kvols, J. Rubin, M.J. O'Connell, J.H. Edmonson, M.M. Ames, J.S. Kovach 53

Phase II Studies

A phase II study of taxol in patients with malignant melanoma – A.I. Einzig, H. Hochster, P.H. Wiernik, D.L. Trump, J.P. Dutcher, E. Garowski, J. Sasloff, T.J. Smith 59

Phase II study of amonafide (Nafidamide, NSC 308847) in advanced colorectal cancer – P.J. O'Dwyer, A.R. Paul, G.R. Hudes, J. Walczak, R.F. Ozols, R.L. Comis 65

Phase II trial of 5,6-dihydro-5-azacytidine in pleural malignant mesothelioma – H.M. Dhingra, W.K. Murphy, R.J. Winn, M.N. Raber, W.K. Hong 69

Phase II evaluation of menogaril (NSC-269148) in non-small cell lung carcinoma. *A Southwest Oncology Group study* – R.B. Vance, J.J. Crowley, J.S. Macdonald, F.R. Ahmann 73

Phase II trial of menogaril in adenocarcinoma of the pancreas. *A Southwest Oncology Group study* – T.D. Brown, P.J. Goodman, T.R. Fleming, L.H. Baker, J.S. Macdonald 77

A phase II study of menogaril in low-grade non-Hodgkin's lymphoma. *An NCI Canada Clinical Trials Group study* – J. Skillings, C. Cripps, E. Eisenhauer, J. Pater, S. Verma, D. Walde 79

Phase II study of 4′deoxydoxorubicin (esorubicin) in advanced or metastatic adenocarcinoma of the stomach – G. Somlo, J. Doroshow, S. Akman, L. Leong, K. Margolin, M. McNamara, P. Multhauf, D. Blayney, R. Morgan, J. Raschko 83

Phase II study of L-alanosine (NSC 153353) in patients with advanced breast cancer. *A Southwest Oncology Group study* – D.D. Von Hoff, S.J. Green, J.A. Neidhart, C. Fabian, T. Budd, J.F. Boyd, C.K. Osborne 87

Phase II clinical trial of 4′-*O*-Tetrahydropyranyl-Adriamycin (THP-Adriamycin) in recurrent squamous cell carcinoma of the head and neck – D.M Shin, A.M. Kramer, I.W. Dimery, M.N. Raber, M. Ewer, W.K. Hong 89

A phase II trial of diaziquone (AZQ) in mixed mesodermal sarcomas of the uterus. *A Gynecologic Oncology Group study* – R.E. Slayton, J.A. Blessing, D. Clarke-Pearson 93

Phase II study of pibenzimol in pancreatic cancer. *A Southwest Oncology Group study* – E.H. Kraut, T. Fleming, M. Segal, J.A. Neidhart, B.C. Behrens, J. MacDonald 95

Phase II trial of N-methylformamide in patients with metastatic melanoma – O. Eton, D.F. Bajorin, E.S. Casper, A.N. Houghton 97

Phase II trial of cisplatin and etoposide in patients with metastatic melanoma – O. Eton, D.F. Bajorin, P.B. Chapman, B.V. Cody, A.N. Houghton 101

Evaluation of fludarabine phosphate in malignant melanoma. *A Southwest Oncology Group study* – J.A. Kish, K. Kopecky, M.K. Samson, D.D. Von Hoff, W.S. Fletcher, R.A. Kempf, F.M. Muggia 105

A phase II trial of gallium nitrate (NSC #15200) in advanced or recurrent squamous cell carcinoma of the cervic. *A Gynecologic Oncology Group study* – J.H. Malfetano, J.A. Blessing, H.D. Homesley, P. Hanjani 109

Phase II trial echinomycin in advanced colorectal cancer. *A Southwest Oncology Group study* – T.D. Brown, P.J. Goodman, T.R. Fleming, S.A. Taylor, J.S. Macdonald 113

Editorial

Reponse rates, duration of response, and dose response effects in phase I studies of antineoplastics – D.D. Von Hoff, J. Turner 115

Instructions for authors 123

Preclinical Studies

Effects of isomeric 2-(Arylmethylamino)-1,3-propanediols (AMAPs) and clinically established agents on macromolecular synthesis in P388 and MCF-7 cells – C.A. Carter, K.W. Bair 125

Adozelesin, a selected lead among cyclopropylpyrroloindole analogs of the DNA-binding antibiotic, CC-1065 – L.H. Li, R.C. Kelly, M.A. Warpehoski, J.P. McGovren, I. Gebhard, T.F. DeKoning 137

Comparative toxicity of fostriecin, hepsulfam and pyrazine diazohydroxide to human and murine hematopoietic progenitor cells *in vitro* – D.-L. Du, D.A. Volpe, C.K. Grieshaver, M.J. Murphy, Jr. 144

Pharmacokinetics of 2′,3′-dideoxyadenosine in dogs – M.G. Wientjes, M.E. Placke, M.J-W. Chang, J.G. Page, W.M. Kluwe, J.E. Tomaszewski 159

A novel N-myristylated synthetic octapeptide inhibits protein kinase C activity and partially reverses murine fibrosarcoma cell resistance to Adriamycin – C.A. O'Brian, N.E. Ward, R.M. Liskamp, D.B. de Bont, L.E. Earnest, J.H. van Boom, D. Fan 169

Clinical Studies

Toxicity trials of amsacrine (AMSA) and etoposide +/– azacitidine (AZ) in childhood acute non-lymphocytic leukemia (ANLL): a pilot study – C.P. Steuber, T. Holbrook, B. Camitta, V.J. Land, C. Sexauer, J. Krischer 181

Mitoxantrone, etoposide, mitoguazone and vinblastine chemotherapy (MV^2) in relapsed and refractory lymphomas – J.P. Crown, S. Gulati, D.J. Straus, J. Kolitz, R. Heelan, J. O'Brien, B.J. Lee, C. Portlock, J. Bertino 185

Phase II trial of esorubicin (4′Deoxydoxorubicin, DxDx) in patients with small cell lung cancer – J.R. Rigas, M.G. Kris, R.J. Gralla, R.T. Heelan, L.D. Marks 187

Esorubicin in advanced endometrial cancer: an ineffective and potentially toxic therapy. *A Southwest Oncology Group study* – J.B. Green, III, S. Green, R.V. O'Toole, D.S. Alberts, W.A. Nahhas, D.L. Wallace 191

Phase II evaluation of fludarabine phosphate in patients with central nervous system tumors. *A Southwest Oncology Group trial* – S.A. Taylor, J. Crowley, F.S. Vogel, J.J. Townsend, H.J. Eyre, K.A. Jaeckle, H.E. Hynes, J.T. Guy 195

Phase I studies of trimetrexate using single and weekly dose schedules – S.D. Huan, S.S. Legha, M.N. Raber, I.H. Krakoff 199

A phase II clinical trial of diaziquone (AZQ) in the treatment of patients with recurrent leiomyosacroma of the uterus. *A Gynecologic Oncology Group study* – R.E. Slayton, J.A. Blessing, K. Look, B. Anderson 207

Meeting report

Working conference on biomodulator and chemotherapy combination therapies – T.D. Brown, M.S. Mitchell, R. Pazdur, S. Wadler, G.R. Weiss 209

Preclinical Studies

Differences in N-acetylation of the experimental antitumor agent batracylin in the mouse and the rat – M.M. Ames, D.A. Mathiesen, J.M. Reid 219

Effects of benzoylphenyl ureas on growth of B16 melanoma cells *in vitro* and *in vivo* – H.P. Hofs, J.G. McVie 227

Antitumor activity and mechanism of action of the marine compound girodazole – F. Lavelle, A. Zerial, Ch. Fizames, B. Rabault, A. Curaudeau 233

Clinical Studies

Phase I study of escalating dose mitoxantrone in combination with α-2-interferon in patients with advanced solid tumors – G. Gasparini, S. Dal Fior, F. Pozza, G.A. Panizzoni, S. Favretto, D.D. Von Hoff 245

Phase II trial of daily oral etoposide in patients with advanced non-small cell lung cancer – S. Saxman, P.J. Loehrer, Sr., K. Logie, D. Stephens, F. Workman, D. Scullin, L.H. Einhorn, R. Ansari 253

Phase II study of intravenous 6-thioguanine in patients with advanced gastric carcinoma – J.A. Ajani, R. Pazdur, R.J. Winn, J.L. Abbruzzese, B. Levin, Ch. Wiseman, M.A. Lenado-Lee, Y.Z. Patt, I.H. Krakoff 257

Phase II evaluation of menogaril in patients with advanced hypernephroma – H.J. Long, M.D. Hauge, T.M. Therneau, J.C. Buckner, S. Frytak, R.G. Hahn 261

Phase II trial of mitoxantrone in acute lymphocytic leukemia of childhood: A Pediatric Oncology Group study – M.L. Graham, J. Estrada, A.H. Ragab, K.A. Starling, D. Rosen, R.W. Wilkenson 263

Phase II study of echinomycin in patients with advanced breast cancer: a report of cancer and leukemia group B protocol 8641 – R.L. Schilsky, D. Faraggi, A. Korzun, N. Vogelzang, J. Ellerton, W. Wood, I.C. Henderson 269

Phase II study of 2'-deoxycoformycin in patients with renal cell carcinoma. *A National Cancer Institute of Canada Clinical Trials Group study* – P. Venner, E.A. Eisenhauer, R. Wierzbicki, J. Johnston 273

Carboplatinum and cytosine arabinoside in patients with disseminated malignant melanoma. *A phase II study* – B. Jeremic, L. Djuric, L. Mijatovic 277

Review Article

Clinical use of thymidine as a rescue agent from methotrexate toxicity – J.L. Grem, S.A. King, J.M. Sorensen, M.C. Christian 281

Review Articles

Terephthalamidine: Past and future – J.S. Fisherman, E.M. Cline, J. Plowman, F.R. Quinn, M.J. Hawkins 295

Ifosfamide pharmacokinetics – L.D. Lewis 305

Preclinical Studies

Antitumor activities of new platinum compounds, DWA2114R, NK121 and 254-S, against human leukemia cells sensitive or resistant to cisplatin – H. Kobayashi, Y. Takemura, H. Miyachi, T. Ogawa 313

Amelioration of thrombocytopenia with concomitant ornithine in sarcoma-bearing rats receiving high dose difluoromethylornithine – V.B. Grossie Jr., D.M. Ota, J.A. Ajani, K. Nishioka 321

Analysis of GSH from primary tumors and its role in *in vitro* chemosensitivities – H. Choy, L. Sulak, G.M. Clark, S. Koester, J.J. Feldmeier 327

Clinical Studies

Phase II evaluation of bisantrene in refractory multiple myeloma. A Southwest Oncology Group study – B.G.M. Durie (for the Myeloma Committee of the Southwest Oncology Group study), J. Crowley, C.A. Coltman Jr., R.A. Chapman, S.P. Balcerzk, J.D. Bonnet, D.A. Lipschitz, R.L. Stephens, B.D. Cheson 329

Phase II trial of ICRF-187 in children with solid tumors and acute leukemia – T. Vats, B. Kamen, J.P. Krischer 333

Phase II trial of indicine N-oxide in relapsed pediatric solid tumors. A report from the Childrens Cancer Study Group – J.S. Miser, W.A. Smithson, W. Krivit, C. Hughes, D. Davis, M. Krailo, D. Hammond 339

Phase II study of Ionidamine in metastatic prostatic carcinoma – D.J. Stewart, S.E. Aitken, A.H. Irvine, D.E. Moors, N.G. Futter 343

A phase II study of chemotherapy of metastatic colorectal carcinoma with 5-fluorouracil plus cisplatin. A Southwest Oncology Group study – R.P. Whitehead, T.R. Fleming, J.S. Macdonald, F.R. Ahmann, H.S. Garewal, J.P. Kuebler 345

Phase II evaluation of menogaril in patients with advanced cervical carcinoma. A collaborative trial of the North Central Cancer Treatment Group and Mayo Clinic – H.J. Long III, H.S. Wieand, J.F. Foley, R.D. Niedringhaus, J.A. Laurie, R.F. Morton, R.M. Goldberg, J.A. Mailliard, G.D. Malkasian, J.H. Edmonson 349

Phase II study of amonafide in advanced pancreatic adenocarcinoma – K. Linke, R. Pazdur, J.L. Abbruzzese, J.A. Ajani, R. Winn, J.E. Bradof, K. Daugherty, B. Levin 353

Hypoprothrombinemia from coadministration of sulofenur (LY 186641) and warfarin: Report of three cases – F.V. Fossella, S.M. Lippman, D.E. Seitz, D.S. Alberts, C.W. Taylor, E. Wiltshaw, J. Hardy, M. O'Brien, T.R. Haynes, R.L. Wolen 357

Phase II evaluation of amonafide in renal cell carcinoma. A Southwest Oncology Group study – C.S. Higano, P. Goodman, J.B. Craig, J.A. Kish, S.E. Rivkin, M. Wolf, E.D. Crawford 361

Phase I – II study of high-dose etoposide in patients with refractory breast cancer – G. Fraschini, F.A. Holmes, L. Esparza, R.L. Theriault, A.U. Buzdar, G.N. Hortobagyi 365

Phase II study of intravenous 6-thioguanine in patients with advanced carcinoma of the pancreas – J.A. Ajani, R. Pazdur, R.J. Winn, J.L. Abbruzzese, B. Levin, R. Belt, J. Young, Y.Z. Patt, I.H. Krakoff 369

Phase II study of fazarabine in advanced head and neck cancer. A Southwest Oncology Group study – J.P. Kuebler, B. Metch, D.E. Schuller, M. Keppen, H.E. Hynes 373

Phase II trial of intravenous 6-thioguanine for unresectable or metastatic non-small cell bronchogenic carcinoma – F.V. Fossella, R.J. Winn, P.Y. Holoye, M.N. Raber, L. Holden, R. Belt, H. Allen, B. Hallinan, K. Harper 375

Phase I trial of FK973: Description of a delayed vascular leak syndrome – R. Pazdur, Dah Hsi Ho, K. Daugherty, W.T. Bradner, I.H. Krakoff, M.N. Raber 377

Erratum for the article by Graham *et al.* (**9**: 263-267, 1991) 383

Announcement 385

Contents Volume 9, 1991 387

Author Index 391

Instructions for Authors 395